CD38 and Miyoshi myopathy: Monoclonal antibodies (moAbs) targeting CD38, such as Daratumumab and Isatuximab, have profoundly improved outcome in relapsed refractory MM (RRMM) and have shown impressive activity as a single agent and in combination with IMiDs and PIs [6,7,8,9,10].